Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarter ended July 31, 2003
Status: Development Stage Company
Operations: The company is engaged in the development of perfluorocarbon-based blood substitutes and therapeutic oxygen carriers, specifically "Oxycyte." It has received FDA approval for an Investigational New Drug (IND) application to begin Phase I safety studies.
Key Financial Metrics
| Metric | Value (July 31, 2003) |
|---|---|
| Cash and Cash Equivalents | $813,676 |
| Total Current Assets | $874,012 |
| Total Current Liabilities | $1,066,080 |
| Working Capital | ($192,068) Deficit |
| Accumulated Deficit | ($19,152,640) |
| Net Loss (Quarter) | ($451,910) |
| Net Loss (Development Stage) | ($19,152,640) |
| Research & Development Expenses (Quarter) | $233,080 |
| General & Administrative Expenses (Quarter) | $226,297 |
| Shares Outstanding | 88,788,874 |
Material Changes vs. Prior Period
- Net Loss: Increased to $451,910 for the quarter ended July 31, 2003, compared to $400,194 in the prior year period. This increase was driven by a reduction in other income (interest income) despite a slight decrease in total operating expenses.
- Research & Development: Increased to $233,080 from $176,289 in the prior year. The increase is attributed to $28,080 in contract manufacturing expenses for Oxycyte, $10,000 for late-stage animal studies, and $15,000 in laboratory wages and supplies.
- General & Administrative: Decreased to $226,297 from $240,594, primarily due to a $18,000 reduction in overseas travel expenses.
- Liquidity: Cash and cash equivalents increased significantly from $178,442 at April 30, 2003, to $813,676 at July 31, 2003, largely due to financing activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. Continuation depends on obtaining additional financing to fund development and testing.
- Financing Activities: The company initiated a $2,000,000 private placement of common stock with foreign investors. As of July 31, 2003, it received $1,017,482 in deposits for 12,718,525 shares. These deposits are recorded as a current liability because signed subscription agreements have not yet been obtained; if agreements are not signed, funds may need to be refunded.
- Outlook: Management believes current cash plus the potential proceeds from the private placement will fund operations through April 30, 2004. The company plans to begin Phase I clinical trials in the third quarter of 2003.
- Risks: Key risks include the inability to obtain FDA approval, failure of clinical trials, inability to secure future financing, and the potential need to refund investor deposits if the private placement is not finalized.
- Related Party Transaction: The company paid $28,080 to a specialty contract manufacturer for Oxycyte production. An officer of the company is a minority shareholder and director of this manufacturer.
Investor Verification Checklist
- Private Placement Status: Verify if the $1,017,482 in deposits have been converted to equity via signed subscription agreements or if they are being refunded.
- Cash Runway: Confirm if the company has secured additional funding beyond the projected April 2004 date, given the history of operating losses.
- Clinical Trial Progress: Monitor the commencement and results of the Phase I safety study for Oxycyte.
- Related Party Terms: Review the terms of the contract manufacturing agreement with the entity where an officer holds a directorship to ensure fair market value.
- Regulatory Filings: Check for subsequent filings regarding the registration of the restricted common stock intended for the private placement.